ChemoCentryx is a biopharmaceutical company focused exclusively on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. Our drug candidates target specific chemokines or chemo-attractant receptors, thereby blocking the inflammatory response driven by that particular chemokine while leaving the rest of the immune system unaffected. Our goal is to discover, develop and commercialize therapeutics with distinct advantages over currently marketed therapies in our disease areas of focus, thereby maximizing shareholder value.
4:00 PM ET on Jul 30, 2014
Delayed at least 20 minutes.
Provided by eSignal.
Jul 23, 2014
ChemoCentryx to Hold Second Quarter 2014 Financial Results Conference Call on Tuesday, August 5, 2014
Jun 3, 2014
ChemoCentryx's CCX168, an Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation in ANCA-Associated Diseases by the FDA
Jun 2, 2014
ChemoCentryx's Orally-Administered Complement 5a Receptor Inhibitor, CCX168, Shows Benefit in ANCA-Associated Vasculitis Based on Birmingham Vasculitis Activity Score and Renal Disease Measurements
View all »Events & Presentations
Aug 5, 2014 at 5:00 PM ET
ChemoCentryx, Inc. Second Quarter 2014 Financial Results Conference Call
^ Return to Top